SUN PHARMA
⚠️ High Risk
FEI: 3015423364 • Mumbai, Maharashtra • INDIA
FEI Number
3015423364
Location
Mumbai, Maharashtra
Country
INDIAAddress
Acme Plaza, , Mumbai, Maharashtra, India
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 7/2/2025 | 64PDY04TRANEXAMIC ACID (HEMOSTATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/6/2025 | 61PCA68SITAGLIPTIN PHOSPHATE (ANTI-DIABETIC) | Division of Southeast Imports (DSEI) | |
| 2/26/2025 | 61PDY68SITAGLIPTIN PHOSPHATE (ANTI-DIABETIC) | Division of Southeast Imports (DSEI) | |
| 9/20/2024 | 61JCY16ROSUVASTATIN CALCIUM | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/7/2023 | 61PDY70DAPAGLIFLOZIN (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/7/2023 | 61PDY31GLIMEPIRIDE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/7/2023 | 61PDY68SITAGLIPTIN PHOSPHATE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/12/2021 | 60XDL28TIMOLOL HEMIHYDRATE (ANTI-ADRENERGIC) | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 9/16/2020 | 61TCA31DOMPERIDONE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/8/2020 | 61TDH31DOMPERIDONE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/29/2020 | 62CAS68OLMESARTAN MEDOXOMIL | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is SUN PHARMA's FDA import refusal history?
SUN PHARMA (FEI: 3015423364) has 11 FDA import refusal record(s) in our database, spanning from 4/29/2020 to 7/2/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. SUN PHARMA's FEI number is 3015423364.
What types of violations has SUN PHARMA received?
SUN PHARMA has been cited for 2 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about SUN PHARMA come from?
All FDA import refusal data for SUN PHARMA is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.